134 related articles for article (PubMed ID: 24176686)
1. Induction of severe systemic lupus erythematosus by TNF blockade and response to an anti-IL-6 strategy: role of IL-17?
Shin JI
J Allergy Clin Immunol; 2013 Nov; 132(5):1257. PubMed ID: 24176686
[No Abstract] [Full Text] [Related]
2. Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy.
Adler S; Kolev M; Varisco PA; Tham M; von Gunten M; Tappeiner C; Villiger PM
J Allergy Clin Immunol; 2013 Apr; 131(4):1235-7, 1237.e1. PubMed ID: 23154083
[No Abstract] [Full Text] [Related]
3. Reply: To PMID 23154083.
Villiger PM
J Allergy Clin Immunol; 2013 Nov; 132(5):1257. PubMed ID: 24176685
[No Abstract] [Full Text] [Related]
4. [Cytokine blockade - a promising therapeutic option in SLE].
Aringer M; Feierl E; Smolen J
Z Rheumatol; 2008 Jul; 67(4):315-7. PubMed ID: 18491117
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.
Kamenarska ZG; Hristova MH; Vinkov AI; Dourmishev LA
Folia Med (Plovdiv); 2015; 57(2):89-92. PubMed ID: 26933777
[TBL] [Abstract][Full Text] [Related]
6. [The management of systemic lupus erythematosus with biological therapies].
Malaise O; von Frenckell C; André B; Malaise MG
Rev Med Suisse; 2013 Aug; 9(395):1507-11. PubMed ID: 24024419
[TBL] [Abstract][Full Text] [Related]
7. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
Clark DN; Markham JL; Sloan CS; Poole BD
Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
[TBL] [Abstract][Full Text] [Related]
9. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
11. Inflammatory bowel disease and lupus: a systematic review of the literature.
Katsanos KH; Voulgari PV; Tsianos EV
J Crohns Colitis; 2012 Aug; 6(7):735-42. PubMed ID: 22504032
[TBL] [Abstract][Full Text] [Related]
12. [Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb].
van Rijthoven AW; van Roon JA
Ned Tijdschr Geneeskd; 2007 Apr; 151(14):839; author reply 839. PubMed ID: 17469329
[No Abstract] [Full Text] [Related]
13. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
Farkas K; Nagy F; Kovács L; Wittmann T; Molnár T
J Crohns Colitis; 2013 May; 7(4):e143-5. PubMed ID: 22818164
[TBL] [Abstract][Full Text] [Related]
14. Treatment of coexistent psoriasis and lupus erythematosus.
Varada S; Gottlieb AB; Merola JF; Saraiya AR; Tintle SJ
J Am Acad Dermatol; 2015 Feb; 72(2):253-60. PubMed ID: 25486913
[TBL] [Abstract][Full Text] [Related]
15. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
[TBL] [Abstract][Full Text] [Related]
16. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
17. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
18. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus.
Brink I; Thiele B; Burmester GR; Trebeljahr G; Emmrich F; Hiepe F
Lupus; 1999; 8(9):723-30. PubMed ID: 10602444
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
20. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
Verma HD; Scherl EJ; Jacob VE; Bosworth BP
J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
